Möchten Sie immer auf dem neuesten Stand bleiben?

Company announcement – No. 50 / 2022 Zealand Pharma to Participate in Upcoming Investor Conferences Copenhagen, Denmark and Boston, MA, U.S. November 8, 2022 – a Zealand Pharma A/S (CVR-no....

Company announcement – No. 49 / 2022 Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022 Copenhagen, Denmark and Boston, MA,...

Press release – No. 7 / 2022 Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting Results from the phase 2 clinical trial of GCGR/GLP-1R dual agonist BI 456906 showing...

Company announcement – No. 48 / 2022 Total number of shares and voting rights in Zealand Pharma at October 31, 2022 Copenhagen, Denmark and Boston, MA, U.S. October 31, 2022 – Zealand Pharma...

Company announcement – No. 47 / 2022 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 46 / 2022 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark and Boston, MA, 10 October 2022 – Zealand Pharma A/S...

Company announcement – No. 45 / 2022 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...

Company announcement – No. 44 / 2022 Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786...

Company announcement – No. 43 / 2022 Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares NOT FOR RELEASE, PUBLICATION OR...

Company announcement – No. 42 / 2022 Total number of shares and voting rights in Zealand Pharma at September 30, 2022 Copenhagen, DK and Boston, MA, September 30, 2022 – Zealand Pharma A/S...